SCM
PRCT icon

Sandler Capital Management’s Procept Biorobotics PRCT Stock Holding History

Sandler Capital Management’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-211,200
Closed -$6.93M – 141
2023
Q3 		$6.93M Sell
211,200
-38,800
-16% -$1.32M 0.71% 57
2023
Q2 		$8.84M Buy
+250,000
New +$8.27M 0.73% 52

Other funds holding PRCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Sandler Capital Management's PRCT Position: Q3 2025 in Review

Sandler Capital Management sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 25,320 shares — an estimated $1.46M sold.

Sandler Capital Management first reported a position in PRCT in Q4 2024 and held it in 3 quarters. The position peaked at $4.2M in Q4 2024. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • Sandler Capital Management reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • Sandler Capital Management sold 25,320 Procept Biorobotics shares in Q3 2025, an estimated $1.46M.
  • Sandler Capital Management first reported a position in Procept Biorobotics in Q4 2024 and held it in 3 quarters.
  • Sandler Capital Management's Procept Biorobotics position peaked at $4.2M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on Sandler Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.